Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Drug Discovery

AI specialist Insilico hails a second drug candidate

by Rick Mullin
August 7, 2021 | A version of this story appeared in Volume 99, Issue 29

Insilico Medicine, a specialist in artificial intelligence–enabled drug discovery, says it has identified a preclinical drug candidate to treat kidney fibrosis. Earlier this year, Insilico identified a novel drug target and novel compound to treat idiopathic pulmonary fibrosis using its AI drug discovery technology. Insilico CEO Alex Zhavoronkov told C&EN that the firm’s success in identifying preclinical candidates “shows you that AI can now really help medicinal chemists accelerate the drug discovery process.” The work also challenges the “myth” that AI will replace medicinal chemists, he says. The company, which has 16 other discovery projects in its pipeline, raised nearly $255 million in series C financing in June.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.